An interventional study of PCCTA scan and Endothelial cell isolation from peripheral blood sample in Coronary Artery Disease (CAD), sponsored by Queen Mary University of London. Recruiting at 1 site in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Queen Mary University of London · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Coronary Artery Disease with a site in United Kingdom — 43 open to participants now, 73 under way, 6 of them phase 3. Coronary Artery Disease · United Kingdom.
Among the 283 studies in Coronary Artery Disease with a site in United Kingdom, this one is the 85th largest by planned enrollment of the 190 interventional ones that give a count, is one of 14 that started in 2026, is one of 114 with no phase, reaches primary completion later than 68 of the 72 other live ones, and was the 281st registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →43 of the 283 studies in Coronary Artery Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
London North West Healthcare NHS Trust · Sites in United Kingdom
Ages 18+
EBI Anti Sepsis BV · Sites in United Kingdom, United States, Belgium and 1 more country
Ages 18+
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 18–80
Queen Mary University of London · Sites in United Kingdom
Ages 18–79
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 25 · Phase 3 28 · Phase 4 21
First in 1998; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 270 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 194 across the 190 interventional studies, 320 across the 93 observational. Of the 167 that completed or were terminated, 49 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
104 of 283 have an industry lead sponsor. The 10 most frequent:
Queen Mary University of London is the lead sponsor of 253 studies on the registry; 58 are open to participants now.
Queen Mary University of London has 7 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Coronary Artery Disease with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07357675Phase 3EBI Anti Sepsis BVA Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery. | 2027-10-01 |
| NCT06951100University of EdinburghMechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation | 2026-12 |
| NCT04604782GE HealthcareA Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | 2026-12 |
| NCT06185530London North West Healthcare NHS TrustSECURE Trial: Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Chronic Coronary Syndrome for Endpoints | 2026-12-31 |
| NCT04286100London North West Healthcare NHS TrustContrast Specific Echocardiogram Versus Left Ventricular Opacification (LVO) Imaging Settings | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 283 studies in Coronary Artery Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Identifying plaques that are at higher risk of progression could help doctors provide earlier and more personalized treatment.
The purpose of this study is to determine whether combining information about blood flow within the coronary arteries with information about a person's biological response to blood flow can improve prediction of plaque growth. Participants undergoing treatment for coronary artery disease will have a specialized heart scan to assess blood flow patterns around plaques in their coronary arteries. Researchers will also collect blood samples to study cells that line blood vessels and investigate how these cells respond to blood flow forces.
The study will follow participants over time to determine whether plaques are more likely to progress in individuals who show a stronger biological response to abnormal blood flow. The findings may help researchers develop new ways to identify patients at higher risk of future heart problems and support the development of more personalized approaches to prevention and treatment of coronary artery disease.
Coronary artery disease (CAD) is caused by the build-up of atherosclerotic plaques within the coronary arteries. While some plaques remain stable, others continue to grow and may develop features associated with an increased risk of rupture, potentially leading to acute coronary events. Identifying plaques that are likely to progress remains a major challenge in cardiovascular medicine and could enable more personalized prevention and treatment strategies.
Wall shear stress (WSS), the frictional force generated by flowing blood on the vessel wall, plays an important role in vascular biology and atherosclerosis. Previous imaging studies using computational fluid dynamics (CFD) have demonstrated that regions exposed to low WSS are more likely to undergo plaque progression and adverse vascular remodelling. However, low WSS alone has limited predictive accuracy because many plaques exposed to low WSS do not progress over time. This suggests that additional biological factors influence how individual patients respond to adverse flow conditions.
Experimental studies have demonstrated substantial variation between individuals in endothelial cell responses to WSS. Endothelial cells line the inner surface of blood vessels and are key regulators of vascular health. These findings support the hypothesis that plaque progression is influenced not only by local haemodynamic conditions but also by patient-specific biological sensitivity to WSS. The POSSEM (Plaque Prediction Obtained with Shear Stress Endothelial Metrics) study aims to evaluate whether combining local WSS measurements with patient-specific endothelial responses improves prediction of plaque progression compared with assessment of WSS alone.
POSSEM is a prospective, longitudinal interventional study enrolling patients with established CAD who are undergoing coronary revascularisation. Baseline photon-counting computed tomography coronary angiography (PCCTA), performed as part of routine clinical care, will be used to reconstruct patient-specific coronary artery anatomy. Computational fluid dynamics will then be applied to these anatomical models to characterize local haemodynamic parameters, including WSS, within coronary plaques.
A peripheral blood sample will be collected from each participant. Endothelial colony-forming cells will be isolated and cultured to provide a patient-specific assessment of endothelial responsiveness to WSS. In laboratory experiments, these cells will be exposed to flow conditions and analysed for molecular markers associated with endothelial activation, inflammation, and cellular stress responses. These analyses will be used to quantify each participant's biological sensitivity to WSS.
Participants will undergo repeat PCCTA imaging approximately 12 months after the baseline assessment, hence, interventional study. Changes in plaque burden and plaque characteristics between baseline and follow-up scans will be evaluated and related to both local WSS measurements and endothelial responsiveness. The study will investigate whether plaques located in regions of low WSS are more likely to progress in patients demonstrating heightened biological responses to WSS compared with those exhibiting lower responsiveness.
Coronary CT datasets will undergo detailed plaque characterization and three-dimensional vessel reconstruction. CFD modelling will be used to estimate local blood flow patterns and WSS throughout the coronary tree. Plaque morphology and composition will be assessed at baseline and follow-up, enabling assessment of disease progression over time. Endothelial cell studies will be performed using standardized laboratory methods to measure flow-responsive biological pathways.
The study is intended as a proof-of-principle investigation of a combined haemodynamic and biological approach to risk prediction. The use of cultured endothelial cells is a research tool designed to establish whether individual responses to WSS contribute to plaque progression. Although this approach is not expected to be used routinely in clinical practice, the findings may support the future development of simpler blood-based biomarkers capable of identifying patients with heightened sensitivity to adverse flow conditions.
Study participation involves collection of a peripheral blood sample and an additional follow-up PCCTA scan. The repeat PCCTA exposes participants to a small additional dose of ionising radiation and requires administration of iodinated contrast material. Appropriate measures will be taken to minimise these risks, including exclusion of individuals with significant renal impairment or known contrast allergy and the use of standard dose-optimised imaging protocols.
This study seeks to improve understanding of the interaction between coronary blood flow and patient-specific vascular biology in atherosclerosis. By integrating haemodynamic and biological information, the study aims to establish whether a combined WSS-biological signature can improve prediction of coronary plaque progression and inform future strategies for personalized cardiovascular risk assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: PCCTA scan · Other: Endothelial cell isolation from peripheral blood sample
During the scans, the patient will be cardiac monitored using ECG synchronisation. PCCTA scan acquisition and parameters will follow Barts Health's standard operating procedures and institutional protocols.
Also known as: Naeotom Alpha scanner
A 50mL blood sample will be collected from consenting patients. The blood will be processed to isolate peripheral mononuclear cells. These cells will be cultured to support the growth of endothelial colony forming cells (ECFCs).
Percentage change in plaque burden over 12 months
Percentage change in plaque burden over 12 months, analysed using linear regression with response to WSS as a continuous predictor
Time frame: From the first CT scan to the second CT scan- 12 months apart
ECFC isolation from peripheral blood sample
Peripheral blood will be drawn at the point of recruitment. Blood will be processed to culture endothelial colony forming cells (ECFCs).
Time frame: The process takes around 4 weeks after blood draw
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2031, 59 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 59 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Mary University of London →